uniQure (NASDAQ:QURE) Insider Kylie O’keefe Sells 15,936 Shares of Stock

uniQure N.V. (NASDAQ:QURE) insider Kylie O’keefe sold 15,936 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This trade represents a 12.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

uniQure Price Performance

Shares of NASDAQ QURE opened at $27.57 on Friday. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The business has a 50 day moving average price of $22.52 and a two-hundred day moving average price of $21.80. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Sell-side analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on QURE shares. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Wolfe Research assumed coverage on uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. The Goldman Sachs Group raised their price target on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Finally, HC Wainwright cut their price target on uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Trading of uniQure

Several hedge funds have recently added to or reduced their stakes in QURE. Torren Management LLC bought a new stake in uniQure during the 4th quarter valued at $28,000. Jones Financial Companies Lllp grew its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter worth $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure in the 4th quarter worth $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter worth $50,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.